Meet Lung Cancer's New Enemy

Novartis (NVS) won early approval for its lung cancer drug Zykadia, making it and Pfizer's (PFE) Xalkori the only ALK-inhibitors approved for treating ALK positive non-small-cell lung cancer.

May 3, 2014 at 10:00AM

Novartis (NYSE:NVS) just won the FDA's approval for its new lung cancer drug, Zykadia, months ahead of schedule. The FDA's move reflects the significant need for new therapies designed to treat less common causes of cancer. In this case, the approval gives doctors a second ALK inhibiting therapy designed to treat patients diagnosed with metastatic ALK-positive non-small cell lung cancer, or NSCLC.

While lung cancer is particularly common, the ALK-positive variation isn't. NSCLC accounts for 85% of all lung cancer cases, but just 2% to 5% of those cases are ALK positive. Because the FDA has given the go-ahead for this new treatment, let's take a closer look at how it may impact Pfizer (NYSE:PFE), which markets Xalkori, the only other approved ALK positive NSCLC drug, and let's also evaluate Zykadia's potential impact on Novartis sales.

NVS Chart

NVS data by YCharts

Second line only
Pfizer's Xalkori won FDA approval back in 2011 following Pfizer demonstrating that the drug doubled progression-free survival rates versus placebo in ALK positive NSCLC patients. As a result, Xalkori has become the standard of care for ALK positive patients, and its sales have climbed sharply. While we won't know how much Xalkori was sold in the first quarter until May 5th, when Pfizer reports earnings, Xalkori's sales grew 129% from 2012 to $282 million in 2013. That growth came thanks to Xalkori winning approval in more than 70 countries.

For now, Xalkori's market share is likely to remain intact given that Xalkori is approved as a first-line ALK positive NSCLC treatment, and Zykadia's approval is as a second-line therapy for patients who have already taken Xalkori, and whose cancer has progressed. While that's a smaller patient pool, the drug's impact on patients shouldn't be diminished. In trials, Novartis gave Zykadia to 163 patients whose disease had progressed following treatment with Xalkori, and about half of those patients saw their tumors shrink.

A big and important market
Every year, more than 220,000 Americans are diagnosed with lung cancer, and sadly, more than 150,000 lung cancer patients die from the disease. That makes lung cancer the second most-common cancer in men and women, and the leading cause of cancer death in the country.

Fortunately, the number of new cases and deaths has been falling during the past decade thanks to advanced cancer screening, public education surrounding the causes of lung cancer, and improving treatment.


Source: National Cancer Institute

However, despite the progress, there remains significant room for improvement given that five-year survival rates remain below 20%. That number becomes even more concerning when we recognize that lung cancer is far more common in the elderly. That means that aging baby boomers are likely to increase the total number of new cases as they reach retirement age.

Currently, about 10,000 baby boomers are turning 65 every day, and roughly two out of every three newly diagnosed lung cancer patients are age 65 or older, according to the National Cancer Institute. Because there are nearly 80 million baby boomers in the United States representing more than a quarter of the country's population, the need for drugs like Xalkori and Zykadia is likely to remain high.

Fool-worthy final thoughts
Drugmakers have plenty of incentive to innovate new lung cancer treatment given that U.S. spending on lung cancer totaled more than $12 billion in 2010, and is projected to grow to as much as $18 billion by 2020. How much of that market Zykadia will capture remains to be seen.

Given the number of lung cancer cases annually, and the percentage of those diagnosed with the ALK version of the disease, roughly 9,500 people are diagnosed with ALK positive NSCLC every year; however, most of those patients will be treated with Xalkori first. So there's definitely an opportunity here, but how much is hard to say for now.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not own shares in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not own shares in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers